Measuring response to neoadjuvant therapy using biomarkers in pancreatic cancer: a narrative review
Chinese Clinical Oncology · 2022-08 · 11 (4) · 30-30
DOI: 10.21037/cco-22-49 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chinese Clinical Oncology, 2022-08. Verfasst von Catherine Valukas und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, McGaw Medical Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Hauptthemen laut MEDLINE: Adenocarcinoma, Pancreatic Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, McGaw Medical Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Department of Surgery, McGaw Medical Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
Zitieren
APA
Valukas, C., & Chawla, A. (2022). Measuring response to neoadjuvant therapy using biomarkers in pancreatic cancer: a narrative review. Chinese Clinical Oncology, 11(4), 30-30. https://doi.org/10.21037/cco-22-49
Vancouver
Valukas C, Chawla A. Measuring response to neoadjuvant therapy using biomarkers in pancreatic cancer: a narrative review. Chinese Clinical Oncology. 2022;11(4):30-30. doi:10.21037/cco-22-49
BibTeX
@article{Valukas2022,
author = {Valukas, Catherine and Chawla, Akhil},
title = {Measuring response to neoadjuvant therapy using biomarkers in pancreatic cancer: a narrative review},
journal = {Chinese Clinical Oncology},
year = {2022},
volume = {11},
number = {4},
pages = {30--30},
doi = {10.21037/cco-22-49}
}
EUVIMED